Open Access

Management of Arrhythmias in Cardiac Dysfunction Patients: ESC Guidelines Update & New Approaches with Landiolol

Event: Heart Failure 2021 Online Congress
Topic: Pharmacotherapy
Session type: Satellite Symposium
Sponsored by AOP Orphan Pharmaceuticals AG
Date: 1 July 2021
Time: 11:20 - 12:05


This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Welcome and introduction.


Intravenous landiolol, a novel β (1)-adrenergic blocker for patients with cardiac dysfunction and atrial fibrillation.

Speaker: Professor H. Puererfellner (Linz, AT)

Questions and answers.


Management of Atrial Fibrillation in patients with cardiac dysfunction. The 2020 ESC Guidelines and the addition of Landiolol.

Speaker: Professor Z. Fras (Ljubljana, SI)

Questions & answers.


2 speakers from this session

Professor Helmut Puererfellner

Ordensklinikum Linz Elisabethinen, Linz (Austria)
16 presentations
0 follower

Professor Zlatko Fras

University Medical Centre of Ljubljana, Ljubljana (Slovenia)
11 presentations
0 follower

This platform is supported by

logo Novo Nordisk